NCT05311618 2024-04-01
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Unknown
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Bay Area Gynecology Oncology